{{Rsnum
|rsid = 603965
|Gene = CCND1
|geno1 = (A;A)
|geno2 = (A;G)
|geno3 = (G;G)
|Orientation=plus
|ReferenceAllele=G
|Chromosome=11
|position=69648142
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Status=Merged
|Merged=9344
|Gene_s=CCND1,LOC100996515
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 30.4 | 41.1 | 28.6
| HCB | 33.6 | 45.3 | 21.2
| JPT | 17.7 | 54.9 | 27.4
| YRI | 3.4 | 28.6 | 68.0
| ASW | 3.5 | 42.1 | 54.4
| CHB | 33.6 | 45.3 | 21.2
| CHD | 37.6 | 42.2 | 20.2
| GIH | 35.6 | 40.6 | 23.8
| LWK | 1.8 | 39.1 | 59.1
| MEX | 19.0 | 37.9 | 43.1
| MKK | 2.6 | 38.5 | 59.0
| TSI | 26.5 | 50.0 | 23.5
| HapMapRevision=28
}}
[[rs603965]] is a SNP in the cyclin D1 [[CCND1]] gene. It is also known as Pro241Pro. The associated genotypes are characterized in terms of their enzymatic activity as High for (A;A), Medium (A;G), and Low (G;G).

In a study of 2 populations of [[breast cancer]] patients (2,000+ patients), increased risk was associated with [[rs603965]](A;A) genotypes in both the Ontario [odds ratio 2.22, CI: 1.49-3.28] and Finland [OR 1.73, CI: 1.08-2.78] populations.{{PMID|18194538|OA=1
}}

{{PMID Auto GWAS
  |PMID=23502783
  |Trait=Multiple myeloma (IgH translocation)
  |Title=The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
  |RiskAllele=G
  |Pval=2E-11
  |OR=1.95
  |ORtxt=[1.61-2.38]
  }}

{{PMID Auto
|PMID=24264314
|Title=Association between CCND1 and XPC polymorphisms and bladder cancer risk: a meta-analysis based on 15 case-control studies
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}